Molecular Diagnosis

01 / UNDERSTAND & APPLY

A molecular signal supports a diagnosis only when its meaning is understood

Molecular diagnosis uses information from molecules such as nucleic acids and proteins to investigate a biological condition. The immediate result is a measured signal: a selected sequence was detected, a particular antigen was captured, or antibodies recognising an antigen were present. Interpretation connects that signal to the clinical or biological question.

The attraction of these methods is that a small amount of a suitable marker can sometimes be detected before obvious symptoms or a large pathogen burden develops. This does not mean every molecular test is always early, perfectly accurate or superior for every question. Sampling, timing, assay design and the nature of the condition determine usefulness.

This lesson compares amplification, hybridisation and immunological recognition. It teaches examination reasoning, not self-diagnosis or an operating laboratory protocol. Actual results require the test’s validated interpretation and an appropriate healthcare context.

02 / UNDERSTAND & APPLY

DNA, RNA, antigen and antibody answer different questions

A nucleic-acid test looks for genetic material selected by the assay. A pathogen-associated sequence may support the presence of that material in the sample; a human sequence variant may provide information about inherited or acquired genetic change. Neither result automatically states the severity of a condition.

An antigen test detects a molecular component recognised by an antibody reagent, often a protein. An antibody test detects part of the person’s immune response. These targets can appear and disappear at different times. Antibody detection is not interchangeable with direct detection of a pathogen component.

A positive antibody result can reflect previous exposure or vaccination in an appropriate test context. It need not prove current active infection, and it does not automatically quantify protection. A negative result early in an immune response may occur before the antibody becomes detectable.

Always complete the sentence: this method detects __ in __. The first blank is the analyte and the second is the specimen. That simple habit prevents a genetic marker, a protein marker and an immune response from being treated as the same observation.

03 / UNDERSTAND & APPLY

Amplification increases a selected DNA signal

Polymerase chain reaction, PCR, uses repeated strand separation, primer binding and DNA synthesis to increase copies of a selected DNA region. The primers define the region being amplified; the enzyme copies from appropriate templates. The method does not copy every molecule in the sample indiscriminately.

For an RNA target, a reverse-transcription step first creates complementary DNA that can enter PCR. Reverse-transcription PCR is therefore conceptually distinct from ordinary DNA-template PCR. Real-time PCR refers to monitoring amplification as it proceeds; the words real-time and reverse transcription describe different features.

Amplification can help detect low initial amounts, but it also makes contamination important. An unwanted matching template can generate a misleading signal. Conversely, inhibitors, poor specimen collection or a mismatch affecting target recognition can contribute to a negative result despite the condition being present.

In an idealised doubling model, N cycles multiply an initial amount by 2 to the power N. Real reactions do not remain perfectly efficient indefinitely, so this is a mathematical model, not a promise of unlimited exponential growth. A signal threshold or cycle count should not be interpreted as a universal clinical scale independent of the assay.

04 / UNDERSTAND & APPLY

A labelled complementary strand locates a target sequence

A nucleic-acid probe is a strand selected to recognise a sufficiently complementary DNA or RNA sequence. Hybridisation is the formation of a paired structure between complementary strands. A label, such as a fluorescent or chemical marker, helps reveal where the probe has bound.

The probe’s sequence recognition and its detectable label have different roles. Complementarity supports targeting; the label supports observation. A radioactive label is one historical option, not a defining requirement for every probe-based method.

A variant can change probe binding, but not every mutation abolishes hybridisation. The effect depends on the probe, mismatch and assay conditions. A probe may also be deliberately matched to a variant rather than to the reference sequence. Therefore no signal does not universally mean mutant, and signal does not universally mean normal.

To interpret a comparison, identify what each probe is intended to recognise and check that the sample and detection system worked. In situ hybridisation retains spatial context in cells or tissues; other formats answer different location or abundance questions. The common principle remains complementary sequence recognition.

05 / UNDERSTAND & APPLY

Enzyme-linked detection converts binding into a measurable signal

ELISA means enzyme-linked immunosorbent assay. Its central idea is specific antigen–antibody binding linked to an enzyme-dependent readout. The enzyme acts on a substrate to produce a detectable change in a suitable assay format. It is not amplifying the target DNA.

In a conceptual sandwich antigen assay, an immobilised capture antibody binds the target antigen and a detection antibody recognises another accessible site. An enzyme-linked detection system reports the bound complex. The antigen is the unknown being detected, while the antibodies are assay reagents.

In an indirect antibody assay, a known antigen can capture antibodies from the sample, and a labelled secondary antibody detects those bound antibodies. Here the sample antibody is the analyte. The same broad technology therefore supports different questions depending on which component is supplied and which is unknown.

Signal intensity depends on assay format and valid measurement conditions. Competitive formats can behave differently from simple increasing-signal models. Do not assume every ELISA uses an identical arrangement or that colour alone establishes a diagnosis without controls and a validated interpretation.

06 / UNDERSTAND & APPLY

A result is trustworthy only if the measurement system is interpretable

A positive control checks that a suitable known target can be detected. A negative control helps reveal background or contamination. An internal control can provide information about the sample or reaction, such as whether inhibition prevented an otherwise expected signal. Different controls answer different failure questions.

A sample-negative result with a failed internal control may be uninterpretable rather than evidence that the target is absent. A signal in the negative control raises concern about contamination or nonspecific background. A confident conclusion requires resolving the relevant control failure.

Detecting nucleic acid does not always establish that a microorganism is viable, and a genetic association does not automatically predict an individual’s outcome. Likewise, a negative test cannot exclude every possible variant if the assay recognises only selected targets. These limitations follow from the scope of the measurement.

Screening aims to identify people who may need further assessment; diagnosis integrates evidence to establish a condition. A screening result and a confirmed diagnosis are not interchangeable labels. Appropriate follow-up depends on the actual test and clinical setting, not on the generic acronym.

07 / UNDERSTAND & APPLY

Change the denominator when you change the question

Clinical sensitivity is the fraction of people with the condition who test positive: true positives divided by true positives plus false negatives. Clinical specificity is the fraction without the condition who test negative: true negatives divided by true negatives plus false positives. The two denominators refer to different reference groups.

Positive predictive value asks a different question: among positive results, what fraction are true positives? Its denominator is all positives, true and false. Even a highly specific test can produce a substantial share of false positives when the condition is rare in the tested population.

Analytical sensitivity concerns how little of the target the measurement can detect under stated conditions; it is not the same as clinical sensitivity across people. An assay can detect a low amount in a controlled specimen yet miss cases because the real specimen contains too little target or was collected at an unsuitable time.

The invented counts below assume a defined reference classification and fixed test behaviour. They teach conditional proportions, not the performance of any named medical product. Real estimates have uncertainty and depend on the tested population and study design.

08 / UNDERSTAND & APPLY

Worked target, control and denominator cases

First identify the molecule, then the measurement, then the inference.

09 / UNDERSTAND & APPLY

Original solved practice

These questions concern concepts, not personal test interpretation.

10 / UNDERSTAND & APPLY

Separate detection from interpretation

Amplification increases selected nucleic-acid signal, probes recognise complementary sequences, and immunoassays report antigen–antibody binding. Identify the analyte and controls before interpreting a result. Sensitivity, specificity and predictive value use different denominators and cannot be exchanged.